DS Pharma Animal Health Announces World’s First Marketing Authorization Approval for a Canine Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cell Product, Stemcure®

DS Pharma Animal Health Co., Ltd. (Head Office: Chuo-ku, Osaka, Japan; President & CEO: Kazuhiro Takada) announced today that it received marketing authorization on March 19 for Stemcure® (development code: A-110), a canine allogeneic adipose tissue-derived mesenchymal stem cell product that is classified as a veterinary regenerative medical product (animal somatic stem cell-processed product). This is the world’s first authorization approval for the manufacture and marketing of a veterinary regenerative medical product whose main ingredient is canine allogeneic adipose tissue-derived mesenchymal stem cells.

You can download the press release from the link below:

Animal Health Innovation Asia 2020

We succesfully had a virtual event of Animal Health Innovation Asia 2020 by Kisaco Research. November 25th was Japan Day, and thanks to Mr. Calan Smith, I was honored to host 3 programs, i.e. “Panel Discussion” by Messrs. Kato, Fukui and Hagihara who are industry leaders from Zoetis JapanZenoaq, and Kyoritsu Seiyaku, respectively, “Innovation Showcase” by 4 start-ups, such as Toletta CatsMT3, Vetamic (Nihon Univ.), and KAICO, and “University Pavilion” by 3 universities, such as Prof. Mizuno of Yamaguchi Univ., Assoc. Prof. Isaka of Rakuno Gakuen Univ., and Dr. Kato of Tokyo Univ. of Marine Science and Technology.
We hope that we can have an offline event, not a virtual one, in Tokyo in 2021.

“Animal Health Innovation Asia 2020” の続きを読む

Current situation and Future of Veterinary Medicines and Related Industries in Japan and the US – New Technologies that Change Future –

The captioned article has been written by Dr. Yuki Ujimasa, DVM, MS, President of AHRMS, Inc., and published on the Journal of the Japan Veterinary Medical Association since October 2019. It recently became public via the following link:
Sorry to say, it is described only in Japanese. The chapters of the article are as follows:
1. Recent activities by multi-national animal health pharmaceutical companies and domestic companies
2. New technologies that can change husbandry industries
3. Impact of emerging and re-emerging infectious diseases in food animals and Possibilities of plant-based meat and cultured meat
4. Telemedicine in veterinary medicines
5. Changes of distribution system and home-delivery in companion animal medicines
6. Necessity for review of veterinary advertising regulations
7. Conclusions
8. Acknowledgment

Animal Health Innovation Asia 2019

We had the 4th Animal Health Innovation Asia 2019 in Tokyo on November 6th and 7th by receiving more than 150 attendee.
We were very happy to support the event as Consulting Partner.
Dr. Yuki Ujimasa, DVM, MS chaired a panel discussion and give two presentations as President of AHRMS, Inc. and President of Vm3, Inc., respectively.

Animal Health Innovation Asia 2019

Animal Health Innovation Asia 2019 will be held on November 6th and 7th at Hotel Westin Tokyo.
We, AHRMS, Inc., are supporting the event as “Consulting Partner” to fix the program, introduce Japanese start-ups and new technologies to multi-national animal health manufacturers and facilitate those companies to enter Japanese animal health markets.